|
2023
|
Invention
|
Compositions and methods for treating brain injury.
Compounds, and compositions, methods, and us... |
|
2022
|
Invention
|
Compositions and methods for treating neurodegenerative diseases.
Compounds, and compositions, m... |
|
2019
|
Invention
|
Compositions and methods for treating neurodegenerative diseases. Compounds, and compositions, me... |
|
2018
|
Invention
|
Compositions and methods for treating brain injury. Compounds, and compositions, methods, and use... |
|
|
Invention
|
Methods for treating post traumatic stress disorder. Compounds and compositions are described her... |
|
2011
|
Invention
|
Β-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists. Substituted 2-(azetidin-2... |
|
|
Invention
|
Methods for treating post traumatic stress disorder. Compounds of the formula: (see above f... |
|
2010
|
Invention
|
Beta-lactamyl vasopressin v1a antagonists.
Novel 2-(azetidin-2-on-1-yl)alkanedioic acid derivati... |
|
2007
|
Invention
|
{beta}-lactamyl vasopression v1a antagonists and methods of use.
Novel 2-(azetidin-2-on-1-yl) al... |
|
|
Invention
|
{beta}-lactamyl vasopression v1a antagonists and methods of use.
Novel 2-(azetidin-2-on-1-yl)alk... |
|
|
Invention
|
Beta-lactam cannabinoid receptor modulators.
Described herein are substituted 2-(azetidin-2-on-1... |
|
|
Invention
|
Beta-lactam cannabinoid receptor modulators. Described herein are substituted 2-(azetidin-2-on-l-... |
|
|
Invention
|
Β -lactamyl vasopressin v2 antagonists. β-lactamyl alkanoic acids and pharmaceutical compositions... |
|
|
Invention
|
Hydroxy and keto-substituted β-lactamyl alkanedioic acids. 3-Hydroxy and 3-keto substituted ... |
|
2006
|
Invention
|
Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists. Substituted 2-(azetidi... |
|
|
Invention
|
Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists. Substituted 2-(a... |
|
|
Invention
|
1a antagonists. 1a receptor
|
|
|
Invention
|
Beta-lactamylalkanoic acids for treating premenstrual disorders. 0-lactamyl alkanoic acids are de... |
|
|
Invention
|
Beta-lactamylalkanoic acids. .beta.-lactamyl alkanoic acid vasopressin V1a receptor antagon... |
|
|
Invention
|
Beta-lactamyl vasopressin v1b antagonists. Substituted 2-(azetidin-2-on-l-yl)alkanedioic acids, s... |
|
2004
|
Invention
|
3-substituted beta-lactamyl vasopressin v1a antagonists.
Novel 2-(azetidin-2-on-1-yl)alkanedioic... |
|
|
Invention
|
3-substituted &bgr;-lactamyl vasopressin v1a antagonists. Novel 2-(azetidin-2-on-1-yl)alkanedioic... |
|
|
Invention
|
1a antagonists. 1a receptor. |
|
2002
|
Invention
|
Beta-lactamyl vasopressin v1a antagonists. Novel 2-(azetidin-2-on-1-yl)alkanedioic acid der... |
